Insurance Restructuring or Co-pay Caps? Testing Nuanced Messages In Charged Pricing Debate
This article was originally published in RPM Report
The drug pricing debate isn’t fun for anyone in the biopharma sector, but it isn’t likely to go away soon. A recent Center for American Progress event highlights the challenges of finding the right message in a sound-bite focused climate – but also the benefits of engaging directly with critics.
Register for our free email digests: